BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Liquid biopsies are reshaping colon cancer detection, particularly in addressing the rise in early-onset cases.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

That is the conclusion of a study in The Lancet, which has tracked the take-up of childhood vaccinations for diseases like ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...

Trying to tackle all challenges at once will likely cause even more issues in the future; instead of spreading out, focus on ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

Global biopharmaceutical company Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at the American Association of Cancer Research ...

Explore the top 5 key takeaways from JP Morgan's 2025 report, covering market access, IRAs, China, AI, and women's health. Stay informed on the latest trends and developments in the financial and ...

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at ...

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.